Please login to the form below

Not currently logged in
Email:
Password:

Proteostasis Therapeutics strengthens leadership team

James DeTore, Geoffrey Gilmartin and Marija Zecevic join

Proteostasis TherapeuticsCambridge, Massachusetts-based Proteostasis Therapeutics has bolstered its leadership team with three new appointments.

James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia.

Meenu Chhabra, president and chief executive officer of Proteostasis Therapeutics, said: “Jim's breadth and depth of experience with small-and-large-scale biotech and pharmaceutical companies will be invaluable as we put into place the financial and operational infrastructure necessary to advance our clinical programme.”

Dr Geoffrey Gilmartin, meanwhile, has been appointed as the company's chief development officer.

Dr Gilmartin joins from AstraZeneca, where he most recently served as its senior medical lead for global medicines development, and has previously worked at Vertex Pharmaceuticals and Beth Israel Deaconess Medical Center.

Chhabra said: “Geoffrey's extensive experience leading clinical development for companies such as AstraZeneca and Vertex Pharmaceuticals will help shape our regulatory and commercial strategies moving forward.”

Lastly, Dr Marija Zecevic takes on the role of vice president of business development, having collaborated with Proteostasis Therapeutics on multiple projects over the past two years.

Prior to this, Dr Zecevic founded Italy-based Zebra Ventures and served as its managing director, and also brings experience from Roche spin-off Bioxell.

Chhabra added: “Marija's track record in driving business development initiatives will further support the execution of value-generating strategic transactions from our DRT platform.”

6th September 2016

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics